155 related articles for article (PubMed ID: 15791458)
1. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
Hollingshead M; Alley M; Burger AM; Borgel S; Pacula-Cox C; Fiebig HH; Sausville EA
Cancer Chemother Pharmacol; 2005 Aug; 56(2):115-25. PubMed ID: 15791458
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.
Tian ZQ; Liu Y; Zhang D; Wang Z; Dong SD; Carreras CW; Zhou Y; Rastelli G; Santi DV; Myles DC
Bioorg Med Chem; 2004 Oct; 12(20):5317-29. PubMed ID: 15388159
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
9. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
10. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
Yin X; Zhang H; Burrows F; Zhang L; Shores CG
Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
Eiseman JL; Lan J; Lagattuta TF; Hamburger DR; Joseph E; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2005 Jan; 55(1):21-32. PubMed ID: 15338192
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effect of N-beta-alanyl-5-S-glutathionyldihydroxyphenylalanine (5-S-GAD), a novel anti-bacterial substance from an insect.
Akiyama N; Hijikata M; Kobayashi A; Yamori T; Tsuruo T; Natori S
Anticancer Res; 2000; 20(1A):357-62. PubMed ID: 10769680
[TBL] [Abstract][Full Text] [Related]
13. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
16. An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo.
Wenyong T; Lu L; Daozhen C; Weidong Y; Ying H
Ann Nucl Med; 2009 Feb; 23(2):113-22. PubMed ID: 19225933
[TBL] [Abstract][Full Text] [Related]
17. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Schluep T; Hwang J; Cheng J; Heidel JD; Bartlett DW; Hollister B; Davis ME
Clin Cancer Res; 2006 Mar; 12(5):1606-14. PubMed ID: 16533788
[TBL] [Abstract][Full Text] [Related]
19. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
Newcomb EW; Lukyanov Y; Schnee T; Esencay M; Fischer I; Hong D; Shao Y; Zagzag D
Anticancer Drugs; 2007 Sep; 18(8):875-82. PubMed ID: 17667592
[TBL] [Abstract][Full Text] [Related]
20. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
